Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Symptoms and General Pathology

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Syndrome

Anemia

Preleukemia

Myelodysplastic Syndromes

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Bone Marrow Diseases

Precancerous Conditions

INCB000928 will be administered in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.

INCB000928 will be administered once daily.

INCB000928

Ekatarine Asatiani, MD

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.

To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma

A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma

Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

To determine the safety and tolerability of INCB000928 administered as monotherapy in participants with MDS or MM.

Defined as the interval from the first onset of anemia response to the earliest date of loss of anemia response.

Defined as the absence of any RBC transfusion

Defined as duration of time for which participants are transfusion independent

Defined as the average number of RBC units

Defined as the increase from baseline in the mean Hgb

Defined as the proportion of participants with CR or PR

Defined as the interval from the first dose of study drug until the first documented progression or death

Defined as the interval from the first dose of study drug until the first documented leukemia transformation or death from any cause.

Defined as the proportion of participants with stringent CR, CR, very good PR, and PR

Defined as the interval from the first dose of study drug until the first documented progression or death.

Maximum plasma concentration of INCB000928

Time to reach maximum (peak) plasma concentration of INCB000928

Area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t.

Effect of INCB000928 on iron homeostasis.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma	NCT04582539	Myelodysplastic... Multiple Myelom... Anemia	INCB000928	18 Years -	Incyte Corporation
To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma	NCT04582539	Myelodysplastic... Multiple Myelom... Anemia	INCB000928	18 Years -	Incyte Corporation
To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma	NCT04582539	Myelodysplastic... Multiple Myelom... Anemia	INCB000928	18 Years -	Incyte Corporation

Spots Global Cancer Trial Database for incb000928

Every month we try and update this database with for incb000928 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for incb000928

Every month we try and update this database with for incb000928 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for incb000928 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.